BioCorRx (BICX) Cash from Operations (2010 - 2026)

BioCorRx has disclosed Cash from Operations across 17 years of filings, most recently posting 432971.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 432971.0, up 37.22% year-over-year; the trailing twelve-month figure through Mar 2026 was 2041639.0 (down 41.17% YoY), and the FY2025 annual result was 2298291.0, down 109.65% from the prior year.
• Cash from Operations came in at 432971.0 for Q1 2026 at BioCorRx, up from 847722.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 126499.0 in Q2 2025 to a low of 872672.0 in Q1 2022.
• The 5-year median for Cash from Operations is 397355.0 (2023), against an average of 454268.88.
• Across the five-year window, Cash from Operations soared 73.72% in 2022 and sank 242.97% in 2025, its largest moves.
• BioCorRx's Cash from Operations stood at 449576.0 in 2022, then slipped by 18.74% to 533836.0 in 2023, then jumped by 53.7% to 247170.0 in 2024, then tumbled by 242.97% to 847722.0 in 2025, then soared by 48.93% to 432971.0 in 2026.
• The last three Cash from Operations figures came in at 432971.0 (Q1 2026), 847722.0 (Q4 2025), and 634447.0 (Q3 2025), per Business Quant data.